定量超声参数在非酒精性脂肪性肝病中的诊断效能
本研究前瞻性纳入74例非酒精性脂肪性肝病疑似患者,以肝活检或MRI为参考标准,评估衰减系数、肝硬度及色散斜率的单独与联合诊断效能。结果显示衰减系数与肝硬度分别对脂肪变和纤维化有较高诊断价值,联合参数可进一步提高对非酒精性脂肪性肝病及高危患者的诊断准确率。
要点
- 衰减系数在脂肪变肝(n=54)中显著高于非脂肪变肝(n=20)(P<0.0001)。
- 肝硬度与色散斜率在纤维化患者(n=37)中均显著高于无纤维化者(n=37)(P=0.0004与P=0.0002)。
- 联合肝硬度与衰减系数诊断脂肪变合并纤维化的AUROCC为0.87(NPV 75%,PPV 77%,P<0.0001)。
核心结论
- 衰减系数和肝硬度分别对检测肝脂肪变和肝纤维化有较高诊断价值,联合衰减系数与肝硬度值可进一步提高对非酒精性脂肪性肝病及高危非酒精性脂肪性肝病患者的诊断准确率。
研究设计与样本
- 前瞻性研究,纳入74例非酒精性脂肪性肝病疑似患者,使用Aplio i800超声扫描仪(Canon Medical Systems,Tustin,CA)于右肝叶获取衰减系数、肝硬度和色散斜率测量值,以肝活检(34例)或MRI(40例)为参考标准。
关键影像表现/征象
- 脂肪变肝(n=54)的平均衰减系数显著高于非脂肪变肝(n=20)(P<0.0001)。
- 肝纤维化患者(n=37)的肝硬度和色散斜率均显著高于无纤维化肝(n=37)(P=0.0004和P=0.0002)。
- 肝细胞气球样变患者(n=23)与无气球样变患者(n=11)之间色散斜率值差异有统计学意义(P=0.02)。
诊断标准与关键数值
- 联合肝硬度与衰减系数检测脂肪变合并纤维化的AUROCC为0.87(NPV 75%,PPV 77%,P<0.0001)。
- 肝硬度检测脂肪变合并纤维化分期≥2患者的AUROCC为0.93(NPV 87%,PPV 82%,P<0.0001)。
- 联合衰减系数、肝硬度和色散斜率及体重指数检测非酒精性脂肪性肝炎的AUROCC为0.87(NPV 80%,PPV 87%,P=0.0006)。
- 活检组中32%(11/34)诊断为非酒精性脂肪性肝炎。
临床应用与阅片要点
- 衰减系数可用于评估肝脂肪变,肝硬度可用于评估肝纤维化,两者联合可提高对非酒精性脂肪性肝病及高危患者的诊断准确率。
- 色散斜率在伴有肝细胞气球样变的患者中呈现显著差异,可能有助于提示非酒精性脂肪性肝炎的组织学特征。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
RATIONALE AND OBJECTIVES: Marked liver steatosis, steatohepatitis, and significant fibrosis are risk factors for unfavorable outcomes in non-alcoholic fatty liver disease (NAFLD). In this study, the diagnostic performance of attenuation coefficient (AC), liver stiffness (LS), and dispersion slope (DS) was evaluated separately and combined in the diagnosis of liver steatosis and fibrosis in NAFLD suspects using biopsy or magnetic resonance imaging (MRI) as a reference standard.
MATERIALS AND METHODS: Seventy-four NAFLD suspects were prospectively imaged with an Aplio i800 ultrasound scanner (Canon Medical Systems, Tustin, CA). AC, LS, and DS measurements were obtained from the right liver lobe.
RESULTS: Thirty-four patients underwent liver biopsy, and 40 had MRI. There were 32 patients (43%) with liver steatosis and fibrosis (S + F), 22 (30%) with steatosis (S), 5 (7%) with fibrosis (F), and 15 (20%) with normal liver (N). Mean ACs were significantly higher in steatotic livers (n = 54) than in non-steatotic livers (n = 20) (P < 0.0001). LS and DS were significantly higher in patients with liver fibrosis (n = 37) compared to non-fibrotic livers (n = 37) (P = 0.0004 and P = 0.0002, respectively). In detecting (S + F), the area under the receiver operating characteristic curve (AUROCC) was 0.87 for combined ultrasound parameters of LS and AC (negative predictive value [NPV]: 75%, positive predictive value [PPV]: 77%, P < 0.0001). In detecting patients with liver steatosis and fibrosis stage ≥2, LS had an AUROCC of 0.93 (NPV: 87%, PPV: 82%, P < 0.0001). In the biopsy group, 32% (11/34) were diagnosed with non-alcoholic steatohepatitis (NASH). DS values showed a significant difference among patients with (n = 23) or without (n = 11) hepatocellular ballooning (P = 0.02). AUROCC was 0.87 for combined ultrasound parameters of AC, LS, and DS with body mass index (BMI) in detecting NASH (NPV: 80%, PPV: 87%, P = 0.0006).
CONCLUSION: AC and LS showed high diagnostic value in detecting liver steatosis and fibrosis, respectively. The combined AC and LS values further improved the diagnostic accuracy in detecting NAFLD and high-risk NAFLD patients.
引用
- Torkzaban M, Wessner CE, Halegoua-DeMarzio D, et al. Diagnostic Performance of Quantitative Ultrasound Parameters in Non-alcoholic Fatty Liver Disease. Acad Radiol. 2023. PMID: 37507328. doi:10.1016/j.acra.2023.07.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。